RxDoctor Payments Data

Malaz Almsaddi, MD

Neurology · Bloomfield Hills, MINPI 1003897562

Payments from drug & device makers

$24,522in general payments, 2019–2025

Across 1,484 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • AbbVie$1K
  • Biogen$1K
  • Sanofi$1K
  • Novartis$988
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$2991%
  • Food & beverage$23,96598%
  • Education$2591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.168$2,371
Neurocrine Biosciences, Inc.66$1,263
AbbVie(2 entities)77$1,135
Biogen61$1,093
Sanofi52$1,070
Novartis78$988
Jazz Pharmaceuticals Inc.59$942
Amgen(2 entities)65$927
EMD Serono, Inc.49$810
Lilly USA, LLC55$762
Catalyst Pharmaceuticals, Inc.36$722
SK Life Science, Inc.35$690
Amneal Pharmaceuticals LLC32$666
Teva Pharmaceuticals USA, Inc.43$642
Pfizer44$633
Argenx US, Inc.30$587
Eisai Inc.28$566
Bristol Myers Squibb38$551
Harmony Biosciences LLC24$511
Lundbeck LLC24$477
Sunovion Pharmaceuticals Inc.33$477
Takeda Pharmaceuticals U.S.A., Inc.19$443
Sumitomo Pharma America, Inc.45$437
Acorda Therapeutics, Inc22$393
Neurelis, Inc.27$372
Supernus Pharmaceuticals, Inc.32$363
Biohaven Pharmaceutical Holding Company Ltd.16$276
Greenwich Biosciences, Inc.9$274
Johnson & Johnson16$256
Alnylam Pharmaceuticals Inc.13$239
Impel Pharmaceuticals Inc.11$231
Corium, LLC11$220
Acadia Pharmaceuticals Inc12$218
CSL Behring11$213
MDD US Operations, LLC15$206
Kyowa Kirin, Inc.11$206
Adamas Pharmaceuticals, Inc.11$186
Otsuka America Pharmaceutical, Inc.9$169
E.r. Squibb & Sons, L.L.C.7$169
Upsher-smith Laboratories LLC7$168
Biohaven Pharmaceuticals, Inc.9$166
Vanda Pharmaceuticals Inc.11$153
Tanabe Pharma America, Inc.7$153
Boston Scientific1$119
Avadel CNS Pharmaceuticals, LLC4$104
Aucta Pharmaceuticals, Inc.5$102
Avanir Pharmaceuticals, Inc.5$77
Azurity Pharmaceuticals, Inc.4$72
Vertical Pharmaceuticals, LLC4$67
Bausch Health US, LLC3$64
Grifols USA, LLC2$61
Nevro Corp.2$56
AstraZeneca3$46
Promius Pharma LLC3$45
Zogenix Inc.3$41
Hospira, Inc.2$37
Arbor Pharmaceuticals, Inc.2$31
Assertio Therapeutics, Inc.2$24
Otsuka Pharmaceutical Development & Commercialization, Inc.1$20
Axsome Therapeutics, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,522 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$334,684
Medicare patients
663
Services billed
2,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate83$125,602
Avonex Pen (4 Pack)Interferon Beta-1a14$118,619
IngrezzaValbenazine Tosylate12$97,179
FycompaPerampanel29$53,752
XcopriCenobamate28$28,597
BriviactBrivaracetam23$27,944
NamzaricMemantine Hcl/Donepezil Hcl25$27,210
Aimovig AutoinjectorErenumab-Aooe23$24,477
Emgality PenGalcanezumab-Gnlm29$22,339
QuliptaAtogepant18$18,385
Nurtec OdtRimegepant Sulfate12$17,590
Lacosamide190$16,634
Memantine Hcl485$15,436
Dimethyl Fumarate31$13,573
NayzilamMidazolam11$13,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$477$125,60283 claims
Neurocrine Biosciences, Inc.Ingrezza$1,263$97,17912 claims
Eisai Inc.Fycompa$566$53,75229 claims
AbbVieNamzaric, Qulipta$1,135$45,59643 claims
UCB, Inc.Briviact, Nayzilam$2,371$41,00534 claims
SK Life Science, Inc.Xcopri$690$28,59728 claims
PfizerNurtec Odt$633$17,59012 claims
Amneal Pharmaceuticals LLCRytary$666$7,50411 claims
Upsher-smith Laboratories LLCTopiramate$168$2,452155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Bloomfield Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →